Scholarlink

Background <p>Ovarian cancer is a major gynecologic malignancy with high morbidity and mortality rates. Current treatment options have limited long-term effectiveness due to tumor resistance and significant side effects.</p> Main body <p>This article explores the potential of belotecan, a derivative of camptothecin, as a promising therapeutic agent for ovarian cancer. Belotecan’s ability to inhibit topoisomerase I, induce DNA damage, and modulate inflammation positions it as a strong candidate for enhancing ovarian cancer treatment. However, challenges such as poor bioavailability, rapid systemic clearance, and dose-limiting toxicity remain. To overcome these issues, nano-formulation strategies are proposed to improve pharmacokinetics, solubility, and tumor-specific targeting. These strategies may enhance belotecan's stability, increase its therapeutic efficacy, and minimize off-target effects.</p> Conclusion <p>This review provides a detailed examination of belotecan’s molecular mechanisms, its anti-inflammatory and anti-cancer properties, and the advances in nano-formulation technologies. The integration of these strategies could lead to more effective treatments and improved outcomes for ovarian cancer patients.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Belotecan in ovarian cancer anti-inflammatory potential and mechanistic insight to nano-formulations

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月13日

查看全文
  • Ajay Kumar,
  • Gesu Singla,
  • Amita,
  • Brahmjot Singh,
  • Pooja Sharma,
  • Sandeep Kaur,
  • Poonam Chaturvedi,
  • Bunty Sharma,
  • Shafiul Haque,
  • Hardeep Singh Tuli

摘要

Background

Ovarian cancer is a major gynecologic malignancy with high morbidity and mortality rates. Current treatment options have limited long-term effectiveness due to tumor resistance and significant side effects.

Main body

This article explores the potential of belotecan, a derivative of camptothecin, as a promising therapeutic agent for ovarian cancer. Belotecan’s ability to inhibit topoisomerase I, induce DNA damage, and modulate inflammation positions it as a strong candidate for enhancing ovarian cancer treatment. However, challenges such as poor bioavailability, rapid systemic clearance, and dose-limiting toxicity remain. To overcome these issues, nano-formulation strategies are proposed to improve pharmacokinetics, solubility, and tumor-specific targeting. These strategies may enhance belotecan's stability, increase its therapeutic efficacy, and minimize off-target effects.

Conclusion

This review provides a detailed examination of belotecan’s molecular mechanisms, its anti-inflammatory and anti-cancer properties, and the advances in nano-formulation technologies. The integration of these strategies could lead to more effective treatments and improved outcomes for ovarian cancer patients.

Graphical abstract